Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [619]

Interrupting breast cancer treatment for young women who desire pregnancy

Dr Olivia Pagani and Dr Ann Partridge

Interrupting breast cancer treatment for young women who desire pregnancy ( Dr Olivia Pagani and Dr Ann Partridge )

No significant difference in recurrence rates among women with DCIS taking...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie...

Treating women with endocrine-resistant HR /HER2 advanced breast cancer ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

No significant difference in recurrence rates among women with DCIS taking...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Estrogen receptor mutations detected in plasma associated with worse overall...

Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer ( Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Analysis of blood samples finds ESR1 gene mutations are prevalent and...

Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Denosumab improves disease-free survival for postmenopausal patients with HR...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant...

Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )

Denosumab improves disease-free survival for postmenopausal HR-positive breast...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

Pathologic complete response to presurgery chemo improves survival for triple...

Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA

Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer ( Dr William Sikov - Women & Infants Hospital of Rhode Island, Providence, USA )

The POSEIDON trial of the EurocanPlatform project

Dr Richard Baird - Cambridge Cancer Centre, Cambridge, UK

The POSEIDON trial of the EurocanPlatform project ( Dr Richard Baird - Cambridge Cancer Centre, Cambridge, UK )

Mouse tumour models in the EurocanPlatform project

Prof Anton Berns - Netherlands Cancer Institute (NKI), Amsterdam, The...

Mouse tumour models in the EurocanPlatform project ( Prof Anton Berns - Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands )

More from ecancer